# Xtant Medical Holdings, Inc.: financial statements, quarterly

XTNT · NYSE · CIK 1453593 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xtnt.md) · [Financials](/companies/xtnt/financials.md) · [Filings](/companies/xtnt/filings.md) · [Insiders](/companies/xtnt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xtnt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.0](/filings/0001493152-24-044764.md) | [28.1 d](/filings/0001493152-25-009391.md) | [27.9](/filings/0001641172-25-009674.md) | [29.9](/filings/0001641172-25-023120.md) | [27.9](/filings/0001493152-25-021512.md) | [31.5 d](/filings/0001493152-26-013792.md) | [32.9](/filings/0001493152-26-022604.md) | [35.4](/filings/0001493152-26-036981.md) | [33.3](/filings/0001493152-25-021512.md) | [32.4 d](/filings/0001493152-26-013792.md) | [20.9](/filings/0001493152-26-022604.md) | [23.0](/filings/0001493152-26-036981.md) |
| Cost of revenue | $m | [9.7](/filings/0001493152-24-044764.md) | [11.0 d](/filings/0001493152-25-009391.md) | [10.6](/filings/0001641172-25-009674.md) | [11.4](/filings/0001641172-25-023120.md) | [11.6](/filings/0001493152-25-021512.md) | [15.5 d](/filings/0001493152-26-013792.md) | [12.7](/filings/0001493152-26-022604.md) | [11.1](/filings/0001493152-26-036981.md) | [11.3](/filings/0001493152-25-021512.md) | [14.6 d](/filings/0001493152-26-013792.md) | [8.9](/filings/0001493152-26-022604.md) | [9.7](/filings/0001493152-26-036981.md) |
| Gross profit | $m | [15.3](/filings/0001493152-24-044764.md) | [17.1 d](/filings/0001493152-25-009391.md) | [17.3](/filings/0001641172-25-009674.md) | [18.6](/filings/0001641172-25-023120.md) | [16.3](/filings/0001493152-25-021512.md) | [16.0 d](/filings/0001493152-26-013792.md) | [20.2](/filings/0001493152-26-022604.md) | [24.3](/filings/0001493152-26-036981.md) | [22.0](/filings/0001493152-25-021512.md) | [17.8 d](/filings/0001493152-26-013792.md) | [12.0](/filings/0001493152-26-022604.md) | [13.3](/filings/0001493152-26-036981.md) |
| Research and development | $m | [0.5](/filings/0001493152-24-044764.md) | [0.5 d](/filings/0001493152-25-009391.md) | [0.5](/filings/0001641172-25-009674.md) | [0.6](/filings/0001641172-25-023120.md) | [0.7](/filings/0001493152-25-021512.md) | [0.5 d](/filings/0001493152-26-013792.md) | [0.4](/filings/0001493152-26-022604.md) | [0.6](/filings/0001493152-26-036981.md) | [0.6](/filings/0001493152-25-021512.md) | [0.5 d](/filings/0001493152-26-013792.md) | [0.4](/filings/0001493152-26-022604.md) | [0.7](/filings/0001493152-26-036981.md) |
| Operating income | $m | [(3.4)](/filings/0001493152-24-044764.md) | [(3.8) d](/filings/0001493152-25-009391.md) | [(3.5)](/filings/0001641172-25-009674.md) | [(2.9)](/filings/0001641172-25-023120.md) | [(3.8)](/filings/0001493152-25-021512.md) | [(1.9) d](/filings/0001493152-26-013792.md) | [1.1](/filings/0001493152-26-022604.md) | [4.6](/filings/0001493152-26-036981.md) | [2.5](/filings/0001493152-25-021512.md) | [(0.9) d](/filings/0001493152-26-013792.md) | [(2.9)](/filings/0001493152-26-022604.md) | [(9.2)](/filings/0001493152-26-036981.md) |
| Interest expense | $m | [0.8](/filings/0001493152-23-041077.md) | [0.8 d](/filings/0001493152-25-009391.md) | [0.8](/filings/0001641172-25-009674.md) | [1.0](/filings/0001641172-25-023120.md) | [1.2](/filings/0001493152-25-021512.md) | [1.1 d](/filings/0001493152-26-013792.md) | [1.0](/filings/0001493152-26-022604.md) | [1.0](/filings/0001493152-26-036981.md) | [0.9](/filings/0001493152-25-021512.md) | [0.7 d](/filings/0001493152-26-013792.md) | [0.6](/filings/0001493152-26-022604.md) | [0.5](/filings/0001493152-26-036981.md) |
| Income tax | $m | [(2.3)](/filings/0001493152-24-044764.md) | [0.6 d](/filings/0001493152-25-009391.md) | [0.1](/filings/0001641172-25-009674.md) | [0.0](/filings/0001641172-25-023120.md) | [0.1](/filings/0001493152-25-021512.md) | [0.0 d](/filings/0001493152-26-013792.md) | [(0.0)](/filings/0001493152-26-022604.md) | [0.3](/filings/0001493152-26-036981.md) | [0.3](/filings/0001493152-25-021512.md) | [1.5 d](/filings/0001493152-26-013792.md) | [0.0](/filings/0001493152-26-022604.md) | [0.1](/filings/0001493152-26-036981.md) |
| Net income | $m | [9.2](/filings/0001493152-24-044764.md) | [(4.3) d](/filings/0001493152-25-009391.md) | [(4.4)](/filings/0001493152-25-021512.md) | [(3.9)](/filings/0001493152-25-021512.md) | [(5.0)](/filings/0001493152-25-021512.md) | [(3.2) d](/filings/0001493152-26-013792.md) | [0.1](/filings/0001493152-26-036981.md) | [3.6](/filings/0001493152-26-036981.md) | [1.3](/filings/0001493152-25-021512.md) | [0.1 d](/filings/0001493152-26-013792.md) | [(3.1)](/filings/0001493152-26-036981.md) | [(9.4)](/filings/0001493152-26-036981.md) |
| Diluted EPS | $ per share | [0.07](/filings/0001493152-24-044764.md) | not reported | [(0.03)](/filings/0001641172-25-009674.md) | [(0.03)](/filings/0001641172-25-023120.md) | [(0.04)](/filings/0001493152-25-021512.md) | not reported | [0.00](/filings/0001493152-26-022604.md) | [0.02](/filings/0001493152-26-036981.md) | [0.01](/filings/0001493152-25-021512.md) | not reported | [(0.02)](/filings/0001493152-26-022604.md) | [(0.07)](/filings/0001493152-26-036981.md) |
| Basic EPS | $ per share | [0.07](/filings/0001493152-24-044764.md) | not reported | [(0.03)](/filings/0001641172-25-009674.md) | [(0.03)](/filings/0001641172-25-023120.md) | [(0.04)](/filings/0001493152-25-021512.md) | not reported | [0.00](/filings/0001493152-26-022604.md) | [0.03](/filings/0001493152-26-036981.md) | [0.01](/filings/0001493152-25-021512.md) | not reported | [(0.02)](/filings/0001493152-26-022604.md) | [(0.07)](/filings/0001493152-26-036981.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.7](/filings/0001493152-24-044764.md) | [5.7](/filings/0001493152-25-009391.md) | [4.5](/filings/0001641172-25-009674.md) | [5.4](/filings/0001641172-25-023120.md) | [6.6](/filings/0001493152-25-021512.md) | [6.2](/filings/0001493152-26-013792.md) | [5.0](/filings/0001493152-26-022604.md) | [6.9](/filings/0001493152-26-036981.md) | [10.4](/filings/0001493152-25-021512.md) | [17.1](/filings/0001493152-26-036981.md) | [12.1](/filings/0001493152-26-022604.md) | [9.9](/filings/0001493152-26-036981.md) |
| Current assets | $m | [64.1](/filings/0001493152-23-041077.md) | [64.9](/filings/0001493152-25-009391.md) | [66.5](/filings/0001493152-24-019887.md) | [69.0](/filings/0001493152-24-030663.md) | [71.4](/filings/0001493152-24-044764.md) | [67.1](/filings/0001493152-26-013792.md) | [69.1](/filings/0001641172-25-009674.md) | [75.6](/filings/0001641172-25-023120.md) | [78.3](/filings/0001493152-25-021512.md) | [78.2](/filings/0001493152-26-036981.md) | [62.6](/filings/0001493152-26-022604.md) | [64.8](/filings/0001493152-26-036981.md) |
| Total assets | $m | [92.0](/filings/0001493152-23-041077.md) | [92.6](/filings/0001493152-25-009391.md) | [93.9](/filings/0001493152-24-019887.md) | [95.6](/filings/0001493152-24-030663.md) | [98.9](/filings/0001493152-24-044764.md) | [93.8](/filings/0001493152-26-013792.md) | [95.8](/filings/0001641172-25-009674.md) | [103](/filings/0001641172-25-023120.md) | [106](/filings/0001493152-25-021512.md) | [94.1](/filings/0001493152-26-036981.md) | [78.0](/filings/0001493152-26-022604.md) | [79.7](/filings/0001493152-26-036981.md) |
| Current liabilities | $m | [21.9](/filings/0001493152-23-041077.md) | [23.0](/filings/0001493152-25-009391.md) | [28.4](/filings/0001493152-24-019887.md) | [28.3](/filings/0001493152-24-030663.md) | [33.7](/filings/0001493152-24-044764.md) | [28.6](/filings/0001493152-26-013792.md) | [29.6](/filings/0001641172-25-009674.md) | [30.6](/filings/0001641172-25-023120.md) | [35.5](/filings/0001493152-25-021512.md) | [29.5](/filings/0001493152-26-036981.md) | [18.8](/filings/0001493152-26-022604.md) | [30.0](/filings/0001493152-26-036981.md) |
| Total liabilities | $m | [37.3](/filings/0001493152-23-041077.md) | [41.3](/filings/0001493152-25-009391.md) | [46.3](/filings/0001493152-24-019887.md) | [50.6](/filings/0001493152-24-030663.md) | [53.2](/filings/0001493152-24-044764.md) | [50.9](/filings/0001493152-26-013792.md) | [52.0](/filings/0001641172-25-009674.md) | [55.0](/filings/0001641172-25-023120.md) | [55.9](/filings/0001493152-25-021512.md) | [43.2](/filings/0001493152-26-036981.md) | [29.4](/filings/0001493152-26-022604.md) | [39.7](/filings/0001493152-26-036981.md) |
| Long-term debt | $m | [14.4](/filings/0001493152-23-041077.md) | [17.2](/filings/0001493152-25-009391.md) | [16.8](/filings/0001493152-24-019887.md) | [21.8](/filings/0001493152-24-030663.md) | [19.1](/filings/0001493152-24-044764.md) | [22.0](/filings/0001493152-26-013792.md) | [22.2](/filings/0001641172-25-009674.md) | [22.3](/filings/0001641172-25-023120.md) | [17.4](/filings/0001493152-25-021512.md) | [11.0](/filings/0001493152-26-036981.md) | [8.1](/filings/0001493152-26-022604.md) | [7.3](/filings/0001493152-26-036981.md) |
| Current portion of debt | $m | [2.8](/filings/0001493152-23-041077.md) | not reported | not reported | not reported | [2.8](/filings/0001493152-24-044764.md) | not reported | not reported | not reported | not reported | [3.5](/filings/0001493152-26-036981.md) | [3.7](/filings/0001493152-26-022604.md) | [3.7](/filings/0001493152-26-036981.md) |
| Shareholders' equity | $m | [54.7](/filings/0001493152-24-044764.md) | [51.3](/filings/0001493152-26-013792.md) | [47.7](/filings/0001493152-25-021512.md) | [45.0](/filings/0001493152-25-021512.md) | [45.7](/filings/0001493152-25-021512.md) | [43.0](/filings/0001493152-26-036981.md) | [43.9](/filings/0001493152-26-036981.md) | [48.5](/filings/0001493152-26-036981.md) | [50.4](/filings/0001493152-25-021512.md) | [51.0](/filings/0001493152-26-036981.md) | [48.6](/filings/0001493152-26-036981.md) | [40.0](/filings/0001493152-26-036981.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,834) d](/filings/0001493152-24-044764.md) | [(915) d](/filings/0001493152-25-009391.md) | [(5,755)](/filings/0001641172-25-009674.md) | [(5,088) d](/filings/0001641172-25-023120.md) | [(1,718) d](/filings/0001493152-25-021512.md) | [665 d](/filings/0001493152-26-013792.md) | [1,278](/filings/0001493152-26-022604.md) | [1,276 d](/filings/0001493152-26-036981.md) | [4,612 d](/filings/0001493152-25-021512.md) | [5,380 d](/filings/0001493152-26-013792.md) | [(2,114)](/filings/0001493152-26-022604.md) | [(7,308) d](/filings/0001493152-26-036981.md) |
| Capital expenditure | $k | [223 d](/filings/0001493152-24-044764.md) | [363 d](/filings/0001493152-25-009391.md) | [773](/filings/0001641172-25-009674.md) | [564 d](/filings/0001641172-25-023120.md) | [2,104 d](/filings/0001493152-25-021512.md) | [672 d](/filings/0001493152-26-013792.md) | [1,191](/filings/0001493152-26-022604.md) | [366 d](/filings/0001493152-26-036981.md) | [430 d](/filings/0001493152-25-021512.md) | [395 d](/filings/0001493152-26-013792.md) | [194](/filings/0001493152-26-022604.md) | [247 d](/filings/0001493152-26-036981.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [93.3](/filings/0001493152-23-041077.md) | [109](/filings/0001493152-24-019887.md) | [109](/filings/0001493152-24-030663.md) | [136](/filings/0001493152-24-044764.md) | [130](/filings/0001641172-25-009674.md) | [130](/filings/0001641172-25-023120.md) | [135](/filings/0001493152-25-021512.md) | [143](/filings/0001493152-26-022604.md) | [149](/filings/0001493152-26-036981.md) | [150](/filings/0001493152-25-021512.md) | [140](/filings/0001493152-26-022604.md) | [140](/filings/0001493152-26-036981.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 140,287,960 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-036981.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.